U.S. CDC recommends re-isolation if COVID recurs after taking Pfizer's pill
 
 
 
 
 
 

U.S. CDC recommends re-isolation if COVID recurs after taking Pfizer’s pill

/ 11:00 AM May 24, 2022
Pfizer's coronavirus disease (COVID-19) pill Paxlovid is packaged in Ascoli, Italy, in this undated image obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS

Pfizer’s coronavirus disease (COVID-19) pill Paxlovid is packaged in Ascoli, Italy, in this undated image obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS

Patients who experience recurrence of COVID-19 symptoms after completing treatment with Pfizer’s drug Paxlovid should isolate again for five days, the U.S. Centers for Disease Control and Prevention said in an advisory issued on Tuesday.

Dozens of individuals have reported rebounding COVID symptoms on social media or to the U.S. Food and Drug Administration after taking Paxlovid, but Pfizer suggests the experience is rare. A recent rise in COVID cases has driven up use of therapeutics in the country.

ADVERTISEMENT

The CDC in its advisory that case reports suggest that recurrence results in mild symptoms, and there have been no reports of severe disease so far. The agency still continues to recommend the oral antiviral drug as a treatment, despite the possibility of recurrences.

A brief return of symptoms may be part of the natural history of SARS-CoV-2 infection in some persons, regardless of treatment with Paxlovid, the agency said.

FEATURED STORIES

CDC recommends that patients with COVID rebound can end their re-isolation period after five full days if there is no fever for 24 hours and symptoms improve, but such patients should wear a mask for a total of 10 days after rebound symptoms begin.

Subscribe to our newsletters! Get updates right into your inbox

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Don't miss out on the latest news and information.
TAGS: COVID-19
For feedback, complaints, or inquiries, contact us.

Subscribe to our newsletters!
Get Updates right into your inbox

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.




We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.